Spike In Drug Recalls Expected As US FDA Resumes Inspections, Targeting COVID-19-Related Problems

Attorneys and recall consultants say any firm distributing products associated with COVID-19 should expect to receive the highest level of scrutiny as the US FDA resumes inspections and uses its enforcement muscle to prohibit companies from making adulterated products, such as hand sanitizers, or making fraudulent claims.

White lightbox with word fda recall on wood background

Attorneys and recall consultants predict a sharp spike in drug recalls reported during the third quarter after the US Food and Drug Administration restarted domestic inspections, targeting firms making adulterated COVID-19 products or making fraudulent claims. 

These observations were made in medical waste services company Stericycle, Inc.’s most recent quarterly recalls report, which compiles recall...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Recalls

More from Policy & Regulation